We have located links that may give you full text access.
Journal Article
Review
Meta-analysis of the clinical effect of Kanglaite injection-assisted gemcitabine plus cisplatin regimen on non-small cell lung cancer.
OBJECTIVE: To systematically evaluate the clinical effect of Kanglaite (KLT) injection-assisted gemcitabine plus cisplatin (GP) regimen on non-small cell lung cancer (NSCLC).
METHODS: The CNKI, WanFang, VIP, Chinese Biomedical Database, PubMed, Embase and Cochrane Library databases were searched to collect the randomized controlled trials (RCTs), which evaluated the clinical effect of KLT combined with GP chemotherapy on NSCLC, published as of February 15, 2023. These articles were screened, extracted and evaluated. Revman 5.3 and STATA 17 were used for analysis, where the odds ratio (OR) was used as the statistic for the binary variables, and the mean difference (MD) was used as the statistic for the continuous variables.
RESULTS: After selection, this meta-analysis included 27 RCTs and 2,579 patients. Comparing with GP chemotherapy, KLT combined with GP regimen enhanced the total response rate ( OR =1.76, 95% CI : 1.49-2.06, P <0.00001), improved the Karnofsky (KPS) score ( OR =2.03, 95% CI : 1.55-2.66, P <0.00001), decreased the adverse reactions, including gastrointestinal reactions ( OR =0.41, 95% CI : 0.33-0.51, P <0.00001), leucopenia ( OR =0.45, 95% CI : 0.35-0.58, P <0.00001), anemia ( OR =0.47, 95% CI : 0.32-0.67, P <0.0001) and liver function damage ( OR =0.52, 95% CI : 0.38-0.73, P <0.0001), as well as elevated immune level, including CD3+ ( MD =8.51, 95% CI : 7.63-9.39, P <0.00001), CD4+ ( MD =5.68, 95% CI : 5.08-6.27, P <0.00001) and CD4+ /CD8+ ( MD =0.41, 95% CI : 0.38-0.44, P <0.00001).
CONCLUSIONS: Current evidence shows that the combination regimen of KLT with GP has shown promising results in increasing the response rate, improving the KPS score, enhancing the immune level, and reducing the incidence of adverse reactions in NSCLC patients. However, this conclusion needs to be further verified due to limitations such as the limited number of articles included in this paper and the variability in research methodology and quality among the included studies.
METHODS: The CNKI, WanFang, VIP, Chinese Biomedical Database, PubMed, Embase and Cochrane Library databases were searched to collect the randomized controlled trials (RCTs), which evaluated the clinical effect of KLT combined with GP chemotherapy on NSCLC, published as of February 15, 2023. These articles were screened, extracted and evaluated. Revman 5.3 and STATA 17 were used for analysis, where the odds ratio (OR) was used as the statistic for the binary variables, and the mean difference (MD) was used as the statistic for the continuous variables.
RESULTS: After selection, this meta-analysis included 27 RCTs and 2,579 patients. Comparing with GP chemotherapy, KLT combined with GP regimen enhanced the total response rate ( OR =1.76, 95% CI : 1.49-2.06, P <0.00001), improved the Karnofsky (KPS) score ( OR =2.03, 95% CI : 1.55-2.66, P <0.00001), decreased the adverse reactions, including gastrointestinal reactions ( OR =0.41, 95% CI : 0.33-0.51, P <0.00001), leucopenia ( OR =0.45, 95% CI : 0.35-0.58, P <0.00001), anemia ( OR =0.47, 95% CI : 0.32-0.67, P <0.0001) and liver function damage ( OR =0.52, 95% CI : 0.38-0.73, P <0.0001), as well as elevated immune level, including CD3+ ( MD =8.51, 95% CI : 7.63-9.39, P <0.00001), CD4+ ( MD =5.68, 95% CI : 5.08-6.27, P <0.00001) and CD4+ /CD8+ ( MD =0.41, 95% CI : 0.38-0.44, P <0.00001).
CONCLUSIONS: Current evidence shows that the combination regimen of KLT with GP has shown promising results in increasing the response rate, improving the KPS score, enhancing the immune level, and reducing the incidence of adverse reactions in NSCLC patients. However, this conclusion needs to be further verified due to limitations such as the limited number of articles included in this paper and the variability in research methodology and quality among the included studies.
Full text links
Related Resources
Trending Papers
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Revascularization Strategy in Myocardial Infarction with Multivessel Disease.Journal of Clinical Medicine 2024 March 27
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app